Afrashteh Nour M, Hajiasgharzadeh K, Kheradmand F, Asadzadeh Z, Bolandi N, Baradaran B (2021) Nicotinic acetylcholine receptors in chemotherapeutic drugs resistance: an emerging targeting candidate. Life Sci 278:119557

Article  CAS  Google Scholar 

Bukowski K, Kciuk M, Kontek R (2020) Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci 21(9):3233

Cai Y, Mei J, Xiao Z, Xu B, Jiang X, Zhang Y, Zhu Y (2019) Identification of five hub genes as monitoring biomarkers for breast cancer metastasis in silico. Hereditas 156:20

Article  Google Scholar 

Dasari S, Njiki S, Mbemi A, Yedjou CG, Tchounwou PB (2022) Pharmacological effects of cisplatin combination with natural products in cancer chemotherapy. Int J Mol Sci. 23(3):1532

Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364–378

Article  CAS  Google Scholar 

Dinić J, Efferth T, García-Sosa AT, Grahovac J, Padrón JM, Pajeva I, Rizzolio F, Saponara S, Spengler G, Tsakovska I (2020) Repurposing old drugs to fight multidrug resistant cancers. Drug Resist Updat 52:100713

Article  Google Scholar 

Dong C, Tian X, He F, Zhang J, Cui X, He Q, Si P, Shen Y (2021) Integrative analysis of key candidate genes and signaling pathways in ovarian cancer by bioinformatics. J Ovarian Res 14:92

Article  CAS  Google Scholar 

Elowe S, Bolanos-Garcia VM (2022) The spindle checkpoint proteins BUB1 and BUBR1: (SLiM)ming down to the basics. Trends Biochem Sci 47:352–366

Article  CAS  Google Scholar 

Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411:342–348

Article  CAS  Google Scholar 

Gao X, Leone GW, Wang H (2020) Cyclin D-CDK4/6 functions in cancer. Adv Cancer Res 148:147–169

Article  CAS  Google Scholar 

Goel S, Bergholz JS, Zhao JJ (2022) Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer 22:356–372

Article  CAS  Google Scholar 

He Z, Chen Z, Tan M, Elingarami S, Liu Y, Li T, Deng Y, He N, Li S, Fu J, Li W (2020) A review on methods for diagnosis of breast cancer cells and tissues. Cell Prolif 53:e12822

Article  Google Scholar 

Hirata Y, Sugie A, Matsuda A, Matsuda S, Koyasu S (2013) TAK1-JNK axis mediates survival signal through Mcl1 stabilization in activated T cells. J Immunol 190:4621–4626

Article  CAS  Google Scholar 

Huang XL, Zhang H, Yang XY, Dong XY, Xie XY, Yin HB, Gou X, Lin Y, He WY (2017) Activation of a c-Jun N-terminal kinase-mediated autophagy pathway attenuates the anticancer activity of gemcitabine in human bladder cancer cells. Anticancer Drugs 28:596–602

Article  CAS  Google Scholar 

Knudsen ES, Kumarasamy V, Nambiar R, Pearson JD, Vail P, Rosenheck H, Wang J, Eng K, Bremner R, Schramek D, Rubin SM, Welm AL, Witkiewicz AK (2022) CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities. Cell Rep 38:110448

Article  CAS  Google Scholar 

Komura K, Inamoto T, Tsujino T, Matsui Y, Konuma T, Nishimura K, Uchimoto T, Tsutsumi T, Matsunaga T, Maenosono R, Yoshikawa Y, Taniguchi K, Tanaka T, Uehara H, Hirata K, Hirano H, Nomi H, Hirose Y, Ono F, Azuma H (2021) Increased BUB1B/BUBR1 expression contributes to aberrant DNA repair activity leading to resistance to DNA-damaging agents. Oncogene 40:6210–6222

Article  CAS  Google Scholar 

Lai W, Zhu W, Xiao C, Li X, Wang Y, Han Y, Zheng J, Li Y, Li M, Wen X (2021) HJURP promotes proliferation in prostate cancer cells through increasing CDKN1A degradation via the GSK3β/JNK signaling pathway. Cell Death Dis 12:583

Article  CAS  Google Scholar 

Latham SL, O’Donnell YEI, Croucher DR (2022) Non-kinase targeting of oncogenic c-Jun N-terminal kinase (JNK) signaling: the future of clinically viable cancer treatments. Biochem Soc Trans 50:1823–1836

Article  CAS  Google Scholar 

Li CL, Liu B, Wang ZY, Xie F, Qiao W, Cheng J, Kuang JY, Wang Y, Zhang MX, Liu DS (2020) Salvianolic acid B improves myocardial function in diabetic cardiomyopathy by suppressing IGFBP3. J Mol Cell Cardiol 139:98–112

Article  CAS  Google Scholar 

Lugones Y, Loren P, Salazar LA (2022) Cisplatin resistance: genetic and epigenetic factors involved. Biomolecules 12(10):1365

Makovec T (2019) Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol Oncol 53:148–158

Article  CAS  Google Scholar 

Mukhopadhyay H, Lee NY (2020) Multifaceted roles of TAK1 signaling in cancer. Oncogene 39:1402–1413

Article  CAS  Google Scholar 

Ni Z, Sun P, Zheng J, Wu M, Yang C, Cheng M, Yin M, Cui C, Wang G, Yuan L, Gao Q, Li Y (2022) JNK signaling promotes bladder cancer immune escape by regulating METTL3-mediated m6A modification of PD-L1 mRNA. Cancer Res 82:1789–1802

Article  CAS  Google Scholar 

Palmer N, Kaldis P (2020) Less-well known functions of cyclin/CDK complexes. Semin Cell Dev Biol 107:54–62

Article  CAS  Google Scholar 

Qiu J, Zhang S, Wang P, Wang H, Sha B, Peng H, Ju Z, Rao J, Lu L (2020) BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway. Cancer Med 9:8159–8172

Article  CAS  Google Scholar 

Qiu Z, Oleinick NL, Zhang J (2018) ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450–464

Article  CAS  Google Scholar 

Riggio AI, Varley KE, Welm AL (2021) The lingering mysteries of metastatic recurrence in breast cancer. Br J Cancer 124:13–26

Article  Google Scholar 

Safa AR (2020) Resistance to drugs and cell death in cancer stem cells (CSCs). J Transl Sci 6(3):341

Article  Google Scholar 

Smith J, Tho LM, Xu N, Gillespie DA (2010) The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 108:73–112

Article  CAS  Google Scholar 

Song M, Cui M, Liu K (2022) Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. Eur J Med Chem 232:114205

Article  CAS  Google Scholar 

Strzyz P (2016) Cell signalling: signalling to cell cycle arrest. Nat Rev Mol Cell Biol 17:536

Article  CAS  Google Scholar 

Su W, Gao W, Zhang R, Wang Q, Li L, Bu Q, Xu Z, Liu Z, Wang M, Zhu Y, Wu G, Zhou H, Wang X, Lu L (2023) TAK1 deficiency promotes liver injury and tumorigenesis via ferroptosis and macrophage cGAS-STING signalling. JHEP Rep 5:100695

Article  Google Scholar 

Suijkerbuijk SJ, van Osch MH, Bos FL, Hanks S, Rahman N, Kops GJ (2010) Molecular causes for BUBR1 dysfunction in the human cancer predisposition syndrome mosaic variegated aneuploidy. Cancer Res 70:4891–4900

Article  CAS  Google Scholar 

Suski JM, Braun M, Strmiska V, Sicinski P (2021) Targeting cell-cycle machinery in cancer. Cancer Cell 39:759–778

Article  CAS  Google Scholar 

Weaver RL, Limzerwala JF, Naylor RM, Jeganathan KB, Baker DJ, van Deursen JM (2016) BubR1 alterations that reinforce mitotic surveillance act against aneuploidy and cancer. Elife 5:e16620

Article  Google Scholar 

Xu G, Niu L, Wang Y, Yang G, Zhu X, Yao Y, Zhao G, Wang S, Li H (2022) HDAC6-dependent deacetylation of TAK1 enhances sIL-6R release to promote macrophage M2 polarization in colon cancer. Cell Death Dis 13:888

Article  CAS  Google Scholar 

Yang Z, Liu D, Zhou H, Tao B, Chang L, Liu H, Luo H, Wang D, Liu W (2021) A new nanomaterial based on extracellular vesicles containing chrysin-induced cell apoptosis through Let-7a in tongue squamous cell carcinoma. Front Bioeng Biotechnol 9:766380

Article  Google Scholar 

Zhang C, Xu C, Gao X, Yao Q (2022) Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics 12:2115–2132

Article  Google Scholar 

Zhou X, Yuan Y, Kuang H, Tang B, Zhang H, Zhang M (2022) BUB1B (BUB1 mitotic checkpoint serine/threonine kinase B) promotes lung adenocarcinoma by interacting with Zinc Finger Protein ZNF143 and regulating glycolysis. Bioengineered 13:2471–2485

Article  CAS  Google Scholar 

Zou Y, Zheng Q, Jiang B, Liu Y, Xu Y, Ma L, Hu Z, Wu M, Song H (2022) Deficiency of PPP6C protects TNF-induced necroptosis through activation of TAK1. Cell Death Dis 13:618

Article  CAS  Google Scholar